Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa randomized double-blind placebo-controlled study of YN001 in men with atherosclerotic cardiovascular or cerebrovascular disease and erectile dysfunction
CTR20253371Phase 2Active
- Sponsor
- Innomed
- Start
- Feb 2026
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of YN001 in erectile dysfunction (ED), atherosclerotic disease, atherosclerotic cerebrovascular disease, sponsored by Innomed. Started Feb 2026; status: active.
02
Drugs
YN001
03
Conditions
erectile dysfunction (ED)atherosclerotic diseaseatherosclerotic cerebrovascular disease
Beyond the preview
Go deeper on CTR20253371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253371.